AstraZeneca (AZN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AZN AstraZeneca

Watchlist

80.890
-2.160-2.60%

Close Sep 9 16:00 ET

80.000
-0.890-1.10%

Post 19:59 ET

250.81BMarket Cap39.27P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Benzinga14:05 ET
AstraZeneca PLC Shares Are Trading Lower After the Company Announced That Datopotamab Deruxtecan Did Not Reach Statistical Significance and Did Not Show an Overall Survival Improvement.
Benzinga14:02 ET
Express News | AstraZeneca Says Datopotamab Deruxtecan Showed Numerical Overall Survival Benefit Over Docetaxel In TROPION-Lung01 Trial, But Did Not Reach Statistical Significance; No OS Improvement Observed
Benzinga13:55 ET
Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients With Advanced Nonsquamous Non-small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
Businesswire13:50 ET
Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Businesswire13:50 ET
J&J Rybrevant/Lazcluze Study Shows Superiority Over Tagrisso
Seeking Alpha13:25 ET

Comments

JovishehMY

Sep 5 09:22

Share Your Profit/Loss

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?

Ryand83

Aug 10 16:18

$LumiraDx (LMDXF.US)$ I think whatever $ROCHE HOLDING AG (RHHBY.US)$ intends to do is going to be massive. Owning 75% or more of the company float means at the bare minimum if this were say a 50B deal Roche would only essentially lose out maximum 10B. I'm just thinking to myself if the other pharmas $AstraZeneca (AZN.US)$ & the other one got a piece of this 🥧 too.

CHFANTA

Aug 1 09:54

$AstraZeneca (AZN.US)$ you can do better~

GraniteShares

Jul 25 12:37

AstraZeneca Earnings Report Q2 2024

AstraZeneca for the second quarter reported total revenue of $12.938 billion, which increased by 13% on a Year-on-Year (YoY) basis. Moreover, On a half-year basis, total Revenue was up by 18% YoY, which stood at $25.617 billion. The revenue growth was driven by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines.

On a segment basis, total revenue growth from Oncology, cardiovascular, renal and metabolism (CVRM), ...

Analyst Rating

No Data

Price Target

No Data

Overall

AZN AstraZeneca

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target